Study of AMG 330 in Combination With Pembrolizumab in Adult With Relapsed or Refractory Acute Myeloid Leukemia
Status:
Terminated
Trial end date:
2020-10-17
Target enrollment:
Participant gender:
Summary
The primary objective of this study is to evaluate the safety and tolerability of AMG 330,
administered in combination with pembrolizumab, in participants with relapsed or refractory
acute myeloid leukemia (R/R AML).